Clinical
RSSArticles
-
Canagliflozin Reduces Cardiovascular Events in Diabetic Patients
Canagliflozin resulted in a lower risk of cardiovascular disease in type 2 diabetics who were at high cardiovascular risk. However, there was a higher risk of amputation, which is a new finding.
-
New Data Show Liraglutide Improves Renal Outcomes in Type 2 Diabetes Patients
In a recent trial, when added to usual care for type 2 diabetes, investigators concluded that liraglutide resulted in lower rates of the development and progression of diabetic kidney disease than placebo.
-
Is This 4:1 Flutter?
The rhythm in the figure was diagnosed as atrial flutter with 4:1 AV conduction. Do you agree? How would you confirm your answer?
-
Clinical Briefs
In this section: treating hypothyroidism in seniors; revisiting penicillin allergies; and new diverticulitis guidance.
-
Sofosbuvir, Velpatasvir, and Voxilaprevir Tablets (Vosevi)
Vosevi is indicated for the treatment of adult patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis who are infected with genotype 1, 2, 3, 4, 5, or 6, and have been treated previously with a hepatitis C regimen containing an NS5A inhibitor.
-
Eat Right, and Live
An improvement in diet over 12 years in middle-aged nurses and other health professionals resulted in a decreased risk of death.
-
Glucose Self-monitoring Not Helpful for Non-insulin-treated Type 2 Diabetes
In this pragmatic randomized trial, self-monitoring blood glucose did not lead to lower hemoglobin A1c levels or improvement in health-related quality-of-life measures.
-
Contraceptive Research: Science Heads to New Frontiers
Funding recently has been awarded to scientists around the globe through the Grand Challenges Explorations program, an initiative funded by the Bill & Melinda Gates Foundation. The program seeks to foster concepts for contraceptive discovery platforms that can contribute to the development of new methods suitable for women and men living in limited resource settings.
-
Increased Focus on Preventing Preeclampsia
Cases of preeclampsia in the United States have increased since 1980 from 2.4% of all pregnancies to 3.8% in 2010. This increase is cause for concern: Preeclampsia accounts for more than $2.18 billion of the healthcare expenditure in the first 12 months after birth.
-
‘Talk. Test. Treat.’ Aimed at Syphilis
There are more reported cases of primary and secondary syphilis in the United States now than there have been in more than 20 years. The Centers for Disease Control and Prevention has issued a call to action to reverse the trend.